CD8A and neoplasm: While the capabilities of Lm to boost CD8+ T-cell responses and remodel immunosuppressive tumor microenvironments may be a unique advantage compared to other platforms, the clinical significance of these findings and the extent to which other vaccine platforms compare has yet to be fully investigated.